Drug trial shows reduced abnormal bone formation in those with fibrodysplasia ossificans progressiva
A multisite, international phase 2 trial evaluating the investigational drug garetosmab has shown that it reduced soft-tissue flare-ups significantly and prevented new areas of abnormal bone formation ...
A study conducted by researchers at Baylor College of Medicine and collaborating institutions reveals the molecular events leading to osteogenesis imperfecta type V, a form of brittle bone disease ...
Ultragenyx Pharma announces phase 3 Orbit & Cosmic results for setrusumab in osteogenesis imperfecta
Ultragenyx Pharma announces phase 3 Orbit & Cosmic results for setrusumab in osteogenesis imperfecta: Novato, California Wednesday, December 31, 2025, 18:00 Hrs [IST] Ultragenyx P ...
Chimeric antigen receptor-T cell (CAR-T cell) therapies have been a significant advance in the field of cancer immunotherapeutics in recent years, particularly for B-cell malignancies. Yet, this ...
Wif1 overexpression accelerated osteogenic differentiation by activating genes related to late-stage osteogenic differentiation and mitophagy processes. Moreover administering Wif1-overexpressing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback